Drug profile · INN
entrectinib
ROZLYTREK
entrectinib (ROZLYTREK) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Drug details — entrectinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
entrectinib (ROZLYTREK) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurotrophic tyrosine kinase receptor inhibitor
Primary target: ALK tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is entrectinib?
entrectinib (ROZLYTREK) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for entrectinib?
ROZLYTREK is a marketed brand name for entrectinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of entrectinib?
entrectinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.